We are live on ! Find out more

BLSM

BlossomHill Therapeutics

BLSM

Market cap $591M

18.59 USD

-0.05

0.27%

At close Updated Oct 1, 4:00 PM EDT

1 day

-0.27%

5 days

-9.14%

1 month

-2.11%

3 months

16.19%

6 months

16.19%

Year to date

16.19%

1 year

16.19%

5 years

16.19%

10 years

16.19%

About: BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Employees: 69

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no approved targeted therapies BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S.

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Primary Markets Group August IPO Update

August's seven U.S. IPOs matched the prior month's deal count, while aggregate proceeds declined modestly. The month saw $1.8 billion in total proceeds compared to the $3.0 billion raised in July and the $2.9 billion raised across seven IPOs in August 2025. Issuance was dominated by the healthcare sector, which priced five deals and accounted for over $1.4 billion of the total proceeds raised.

Primary Markets Group August IPO Update

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that updated data from the ongoing Phase 1/2 SOLARA trial describing anti-tumor activity of BH-30643 in patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S will be shared as a mini-oral presentation on September 15, 2026 at the 2026 World Conference on Lung Cancer in Seoul, South Korea.

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC) after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI). BH-30643 is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial enrolling patients at more than 40 sites in 10 countries.

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

See News Rankings

Price charts implemented using Lightweight Charts™